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Cancer is the second l eading cause of death in the 
United States. The risk of cancer development and 
subsequent death from the disease increases sharply in the 
population over 55 years of age(1) . Coagulation problems 
also increase with age and have been 
increasing the metastatic spread of cancer. 
implicated in 
Although cancer 
treatment has improved constantly it still remains quite 
toxic and improvements are needed. 
Heart disease, cancer , and cerebrovascular disease rank 
respectively one , two, and three as the leading causes of 
death in the United States . There are over 729 , 510 deaths 
per year from heart disease , approximately 440,000 deaths 
per year from cancer , and over 175,629 deaths per year from 
cerebrovascular disease(1) . 
Approximate ly 855 ,000 new cases of cancer are diagnosed 
each year along with the above mentioned 440,000 deaths . 
Over 83% of cancer deaths occur in patients over 55 years of 
age. In all cases the five year survival is less than or 
equal to 50% in patients with metastatic disease(1). 
Arterial and venous thromboembolism contribute to many 









anticoagul ants in the treatment of certain malignancies is 
2 
growi ng in animal(3 , 4) and human(5- 8) studies . 
Anticoagulants (e.g. heparin and warfarin) , platelet-
inhibi tory agent s (e . g. aspirin , dextran , and dipyridamole) , 
and fibrinolytic agents (e . g. urokinase and streptokinase) 
have all been reported to inhibit tumor groHth. In 
contrast , conditions Hhich increase coagulati on enhance 
metastas i s formation(?) . 
The concept of met a s tas i s implies t hat a cancer cel l 
must separate from a primary l esion, move to a di stant 
l ocation , and attach t o vascular endothelium . In animal 
studies , many investigators have pointed to the common 
association between arrested tumor emboli , fibrin- containing 
thrombi and pl atelets ; and t hey have stressed the role of 
these inter actions in preci pitat i ng the attachment of 
circul ating malignant cells(9) . To prevent the process of 
hematogenous metast asis fo r mation , inhibi t i on must occur at 
one of these four level s : 1) at the growth of the primary 
lesion, 2) at the point of invasion of the vessel walls , 3) 
at the point of r el ease of viable tumor cells , or 4) at t he 
point of entrapment and gro\.,rth in d i stant organs . 
inhibits t he entrapment of circulating tumor 
pr esumably through coagul ative mechanisms(10) . 
Warfarin 
cells 
Once a metastatic cell becomes attached it requires 
blood vessels from t he hos t in order to grow . Thi s event is 
triggered by the tumor cells when they release a diffusable 
chemi cal substance called tumor angiogenesis f actor (TAF) . 
This subst ance has the capacity t o s timulate nearby blood 
3 
vessels to send out new capillaries that grow toward the 
small colony of tumor cells and penetrate it( 11) . 
Dvorak , et . al.(12) , in 1979 , hypothesized that tumors 




a protective fibrin-gel by 
of activating the host's 
clotting and fibrinolytic systems . Dvorak suggests that 
this fibrin-gel (cocoon) around t he tumor might enable the 
tumor cells to develop without challenge from the host's 
immune surveillance system. Four distinct mediator 
activities were recognized in the tumor experiment with 
strain 2 guinea pigs. They found that line 10 tumor cells 
secreted a vascul ar permeabili ty f actor ( VPF ) , a 
procoagulant (PC) , a plasminogen activator (PA), and a 
macrophage-migration inhibitory factor . (MIF) , 
nonmalignant control cells secreted none of these . 
\olhile 
There 
was one exception in that rabbi t kidney cells released a 
PA activity, presumably urokinase. 
Many tumors have tumor-specific antigens on their 
surfaces with the capability of evoking either humoral or 
cell-mediated immune response from the host(13) . With the 
protective fibrin-gel, these antigens can be masked from the 
host allowing the tumor to go undetected . 
Warfarin depresses the synthesis in the liver of 
several factors which are known to be active in the 
coagulation mechanism l eading to fibrin formation . By 
inhibiting fibrin formation , warfarin could lead to 
increased detection of tumor by the host. If the fibrin-gel 
4 
is instrumental in angiogenesis then production of new blood 
vessels to the tumor woul d also be inhibited , thus leading 
to decreased t umor growth and increased tumor death. As an 
anticoagulant, warfarin would al so assis t in r educing 
coagulation problems associ ated with cardiovascular disease 
and increased metastas i s format i on in cancer patients . 
Since the populati on over 55 years of age is at the greatest 
risk in all three categories (i . e . heart disease , cancer , 
and cerebrovascular disease) , it seems logical that patients 
in this age group could benefit( 1 ,1 4-16) from anticoagul ant 
therapy . Also, it is not uncommon for these pat ients to 
have more t han one of t hese three death- causing diseases , 
and their gain could be even more significant . 
As stated above , studies i ndicate that anticoagulants 
may be beneficial in the treatment of certain malignant 
tumors by inhibiting tumor metastasis . Warfarin as an 




The therapeutic dose of warfar in has been 
and it is effective orally . Its risk of 
can be minimized by monitoring the 
prothrombin time , and its side effects , other than 
hemorrhage, are rare . If toxic doses of warfarin are given , 
the effects on the coagulati on mechanism can be readily 
reversed by vitamin K and/or transfusion therapy(?) . 
Therefore , warfarin is a logical drug to use in conducting 
the study . 
Another factor important in disea se control i s host 
5 
immune surveillance. I f the fibrin-gel is tumor 
protecti ve(J ,4,1 2) , then removal of the gel should expose 
the tumor to normal defensive mechanisms . Based on animal 
studies by Folkman(1 1) and Santer(17), this tumor exposure 
to immune surveillance shoul d then produce altered leukocyte 
activity . Shortly after the start of warfarin therapy , 
normal immune response should increase 
in neutrophils (PMNs) and macrophages in the area of 
the tumor. There should also be an increase in T-
lymphocytes , B-lymphocytes and null-lymphocytes. B-
lymphocytes should then be s timulated to produce antibodies 
t o the exposed tumor surface antigens allowing complement 
fixation, K cell activity , and tumor death(17) . 
Nucl ear medicine techniques using I ndium-111 Oxine now 
al low l abeling of cel lular bl ood components so that immune 
responses can be observed in humans . Indium- 111 Oxine forms 
a nonpolar l i pophilic complex useful for labeling platelets 
for t hrombus detection , and leukocytes (WBCs) for leukocyte 
kinetic studi es . The labeled WBCs can t hen be used to 
locate infection , inflammation, or tumorcidal activity(18). 
Indium-1 11 Oxine has been reported to have no side effects 
and to be safe as a diagnostic agent in humans(19) . 
MATERIALS AND METHODS 
Mouse mammary tumor is a common form of cancer used for 
experimental animal study . This investigation was designed 
to study the nature of leukocyti c response to mouse mammary 
tumor implants in C3H/HeJ mice with and without 
anticoagul ants . The main thrust of the research was in 
three ar eas : first, to develop a backgr ound in light 
microscope morphology of spontaneous mouse mammary tumor and 
its change with first and second passage into normal mice ; 
second , to analyze change in leukocytic response in sham 
operat ed , tumor - and liver - i mplanted mi ce ; and third , to 
analyze changes in leukocytic response to tumor implants 
with and without anticoagulation . 
Experiment I: Li ght Microscope Morphology of 
Spontaneous and Passaged C3H/HeJ Mouse Mammary Tumors . 
Goal : To become familiar with the parenchyma and 
stroma of spontaneous and passaged C3H/HeJ mouse mammary 
tumors in order to evaluate morphologic responses to 
experimenta l procedures . 
Method : Four C3H/HeJ mice with spontaneous mammary 
tumors were sacrificed using diethyl ether . The dorsal 
surface of the dead mouse was swabbed with 70% ethanol , an 
incision made , skin retracted and pinned back , and the t umor 
6 
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carefully dissected from the surrounding tissue of each 
mouse. When separated from the surrounding tissue , the 
tumor was washed several times in sterile i sotonic saline. 
A portion of the tumor was then dissected into pieces 
weighing approximately 10 mg. (Tumor not required for 
implantation was fixed in 10% formalin and paraffin slides 
prepared.) A single segment (approximately 10 mg) was 
implanted into each of two virgin female C3H/HeJ mice using 
a 23 gauge trocar . The trocar was introduced subcutaneously 
into the tissue via a skin incision and directed toward the 
implantation site midway between the left shoulder and l eft 
hip in the axillary line . Tumor implantation was completed 
by introducing a plunger into the barrel of the trocar . A 
clockwise , followed by a counter- clockwise, rotation of the 
plunger insured complete evacuation of the t umor . The 
trocar and plunger were then carefully removed . No 
sutures were r equired to repair the skin incision . Three 
weeks after the implantation the two mice (first passage) 
were sacrificed and the tumors removed and prepared in a 
manner like that described above. A segment of tumor from 
one mouse was then implanted into one normal mouse and a 
segment of the second tumor into a second normal mouse . 
Three weeks lat er the two mice (second passage ) were 
sacrificed and the tumor removed and fixed in 10% formalin 
with paraffin slides prepared (Table I) . 
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Table I 
EXPERI MENT I 
(TUMOR IMPLANT PASSAGE) 
FOUR C3H/HeJ MICE WITH SPONTANEOUS MAMMARY TUMORS 
DAY ST1 ST2 ST3 ST4 
DAY 22 TP1 -1 TP2- 1 TP3-1 TP4-1 
TP1 - 1 TP2- 1 TP3- 1 TP4- 1 
DAY 43 TP1 - 2 TP2-2 TP3- 2 TP4- 2 
TP1 - 2 TP2- 2 TP3- 2 TP4- 2 
(ST1 , ST2 , ST3, ST4) repr esents spontaneous t umor mice 
numbers 1, 2 , 3 , and 4. 
(TP1 - 1 , TP2 - 1, TP3- 1 , TP4-1) represents transplant number 1 
from each spontaneous tumor mouse number 1, 2 1 3 , and 4. 
(TP1-2 , TP2- 2, TP3- 2, TP4-2) represents t r ansplant number 2 
from each spontaneous tumor mouse number 1 , 2 , 3 , and 4. 
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Experiment II : Leukocytic Response in Sham operated , 
Tumor- and Liver-implanted CJH/HeJ Mice . 
Goal: To characterize the leukocytic response to 
implanted CJH/HeJ spontaneous tumor segments by contrasting 
that response with those of syngeneic mice wi th implants of 
normal (liver) tissue and mice that were sham operated upon . 
Method : To obtain material f or implantation , a female 
donor CJH/HeJ mouse with a spontaneous mammary tumor and a 
normal mouse were sacrificed using diethyl ether . 
The dorsal surface of t he dead tumor mouse was swabbed 
with 70% ethanol, an i nc i sion made , skin retracted and 
pinned back , and the tumor car efully dissected from the 
surrounding tissue . When separat ed from surroundi ng tissue , 
the t umor was washed several t i me s in sterile i sotonic 
sal i ne . The tumor was then dissected i nto pieces weighing 
approximately 10 mg . A s i ngl e tumor segment (approximately 
10 mg) was then implanted into each of 12 virgin fe male 
CJH/HeJ mice using a 23 gauge trocar . The trocar was 
i ntroduced subcutaneously into the tissue via a skin 
incision and directed toward t he implantation site midway 
betwe en the l eft shoulder and left hip in the axillary l i ne . 
Tumor implantation was compl et ed by introducing a plunger 
into the barrel of the trocar. A clockwise, followed by a 
counter-clockwise , rotation of the plunger insured complete 
evacuation of the t umor . The trocar and plunger were 
carefully removed . No sutures were required to r epair the 
10 
skin incision . 
The anterior surface of the dead normal mouse was 
swabbed with 70% ethanol , an incision made , skin retracted 
and pinned back , and the normal liver was carefully removed 
from the mouse. When separated the liver was then dissected 
into pieces weighing approximately 10 mg . A second group 
had a single l iver segment (appr oximately 10 mg) implanted 
into each of 12 virgin female C3H/HeJ mice using a 23 gauge 
trocar . The trocar was introduced subcutaneously into the 
tissue via a skin incision and directed to~.o1ard the 
implantation site midway between the left shoulder and 
l ef t hip in the axillary l ine . Liver i mplant ation was 
completed by introducing a pl unger into the barrel of the 
t r ocar . A clockwise , fol lowed by a counter-cloch1ise , 
rotation of the pl unger insured complete evacuation of the 
liver . The trocar and plunger were then carefully 
removed . No sutures were required to r epair the skin 
inci sion . 
A third group of 12 virgin f emale C3H/HeJ mice had the 
empty 23 gauge trocar introduced subcutaneously tissue via a 
skin incision and directed toward the implantation site 
midway between t he l eft shoulder and l eft hip in the 
axillar y line. A plunger 1.o1as introduced into the barrel of 
the trocar and cloc~vise, f ollowed by counter-clockwise , 
rotation of the plunger was performed . The trocar and 
plunger were carefully removed . No sutures were required 
to repair t he skin incision . 
:... 
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Three mice from each group were sacrificed on day 1 (24 
hours after implant operation), day 2, day 4 , and day 8 
(Table II). 
A posterior full midline incision was made and the skin 
flap pi nned and observed . The tumor , liver , or sham track 
was removed in block (with skin attached) and fixed in 10% 
formalin with paraffin slides prepared . 
The slides from each group were observed for a change 
in leukocyte activity around the tumor , liver or sham 
implant site . Procedures for measuring change are further 
detailed under method of analysis (p .1 4) . 
Experiment III : Effects of Heparin and Warfarin on 
C3H/HeJ Mouse Mammary Tumor Impl ant: Leukocyt ic Response 
Alterations . 
Goal : To describe changes in l eukocyti c response t o 
tumor implants in control mice versus tumor-bearing 
mice receiving heparin or warfarin . 
Method: To obtain material for implantation , a female 
donor C3H/HeJ mouse with a spontaneous mammary t umor was 
sacri ficed using diethyl ether . The dorsal surface of the 
dead mouse was swabbed with 70% ethanol , an incision made , 
skin retracted and pinned back , and the tumor carefully 
dissected from the surrounding tissue . When separated from 
the surrounding tissue, the tumor was washed several times 
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into pieces weighing approximately 10 mg . A single t umor 
segment (approximately 10 mg) was implanted into each of 36 
virgin female C3H/HeJ mice using a 23 gauge trocar . The 
trocar was introduced subcutaneously into the tissue via a 
skin incision and directed toward the implantat ion site 
midway between the left shoulder and left hip along the 
axillary line . Tumor implantation was completed by 
introducing a plunger into the barrel of the trocar . A 
clockwise , followed by a counter- clockwise , rota tion of the 
plunger insured complete evacuation of the tumor . The 
trocar and plunger were then carefully removed . No 
sutures were required to r epair the skin incision . 
The 36 mice were divided into three groups of 12 mice 
each . Twelve mice i n the control group were given 0 . 01 ml 
per gram of mouse weight (point body weight concentration) 
of normal saline (0 . 9% sodium chloride) inj ected 
intraperitoneally (i . p .) once a day started day - 3 (day 
-3 refers to injections started 3 days before the tumors 
were impl anted) and continued through day 14 . 
Twelve mice were in the warfarin group with 0 . 01 ml 
per gram of mouse weight of a point body weight equivalent 
to 0 . 75 mg/kg injected i . p . once a day from day - 3 and 
continued through day 14 . 
Twelve mice were in the heparin group with 0 . 01 ml per 
gram of mouse weight of a point body weight concentration 
equivalent to 0 . 4 mg/kg inj ected i . p . twice a day started on 
day -3 and continued through day 14 . 
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Two mice from each group were sacrificed on days 2, 4 , 
7, 9, 11 and 14 (Table III). 
After sacrifice , a 
made and the skin flap 
removed in block and 
slides prepared . 
posterior full midline incision was 
pinned and observed . The tumor was 
fixed in 10% formalin with paraffin 
The slides from each group were analyzed for change in 
leukocytic response to tumor implants in control mice 
versus tumor - bearing mice receiving heparin or warfarin. 
Method of Analysis : Both experiments II and III were 
anal yzed in the same manner using a Nikon micro scope with a 
Nikon transformer light sour ce . 
performed from a microscopic view 
border of the tumor was located 
The observat ions wer e 
of 400 power . The 
under the microscope 
at 40 to 1 00 power . The interface of the tumor \oJi th the 
infiltrative boundary was then viewed at 400 power . The 
left 10 power optic of the microscope was equipped with a 65 
X 45 mm . r ectangular box with a cross- hair dividing the box 
in half . The box was positioned \'<'i t h the cross-hair 
dividing the interior (tumor portion of the slide) from the 
boundary (the infiltrative interface around the tumor) . A 
physical count of the cells in each half of the square was 
performed . One-half of the total box outlined the area (or 
field) of the cell count for the interior and the other half 
of the box outlined the area of the count in the boundary . 
The cells were counted and classified as polymorphonuclear 




TUMOR- IMPLANTED CJH/HeJ MICE WITH AND WITHOUT ANTICOAGULANTS 
(TOTAL OF 36 MICE DIVIDED INTO J GROUPS) 
CONTROL HEPARIN WARFARIN 
(SALINE) 
12 MICE 12 MICE 12 MICE 
-----------------------------------------------------------
DAY 2 2 2 2 
DAY 4 2 2 2 
DAY 7 2 2 2 
DAY 9 2 2 2 
DAY 11 2 2 2 
DAY 14 2 2 2 
16 
or tumor cells . The cell counts were then verified by 
a second person . A total of three separate observations and 
counts was performed on each tumor block for each mouse . 
The numbers generated from the cell counts in the 
boundary , and the interior were then combined into groups . 
In Exper iment II one group was made up of those mice 
sacrificed from day 1 through day 4 and the second group was 
represented by those mice sacri ficed on day 8 . In 
Experiment III the two groups consis t ed of mice sacrificed 
on days 2 through 4 and mice sacrificed on days 7 through 
14. The se data were then statistically evaluated using the 
Dunnett ' s-t test for two or more groups and compari sons 
were made to normal immune responses in t he contr ol gr oups . 
RESULTS 
Table IV of Experiment I represents a list of the data 
obtained from microscopic observations at 400 power . These 
data were not statistically evaluated since the experiment 
was conducted for the purpose of familiarization for the 
investigator. 
Statistical Comparisons 
Tables V through XIV represent the raw data from 
Experiment II while Tables XV and XVI report the mean data 
and corresponding standard error of the mean. 
Table XV shows an increase (P<0 . 05) in the number of 
PMNs in response to tumor-implant when compared to the sham 
operated group . Lymphocyte activity is also increased 
(P<0 . 01) for both liver and tumor implants when compared to 
the sham operated group . Histiocyte r esponse 
increased (P<0.05) in the liver- i mplanted group 
was 
\.Jhen 
compared to the sham operated group . A highly significant 
difference in the number of fibroblasts (P<O . 01 ) was 
observed around the boundary in the day 1 through 4 liver-
and tumor-implanted mice . The number of fibroblasts was 
significant ly l ower a r ound the tumor and the liver 
implants . 
Table XVI shows an increase (P<0 . 05) in the lymphocytic 
response on day 8 in the tumor-implanted group when compared 
to the l iver-implanted group . Shown also i s a decrease 
17 
18 
(P<0 . 05) in the number of histiocytes appearing in t he 
interior of the tumor-implanted group between days 1 and 4 




Raw Data for Light Microscope Morphology of Spontaneous 










































































(ST1, ST2 , ST3 , ST4) represents spontaneous tumor mice 
numbers 1 , 2 , 3, and 4. 
(TP1-1 , TP2-1, TP3-1 , TP4-1 ) represents transplant number 
from each spontaneous tumor mouse number 1, 2 , 3, and 4. 
(TP1-2 , TP2-2 , TP3-2 , TP4- 2) represents transplant number 2 





Raw Data fo r Boundary of Sham Operated C3H/HeJ Mi ce 
-----------------------------------------------------------
Sample No. Day PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 9 1 1 5 
2 4 1 7 16 
3 1 0 7 15 
4 1 0 0 9 0 
5 1 0 0 6 11 
6 1 0 1 7 4 
7 1 5 2 7 3 
8 1 5 2 10 1 
9 1 4 2 6 4 
10 2 9 8 8 0 
11 2 0 1 7 14 
12 2 0 0 16 15 
13 2 3 5 14 0 
14 2 0 1 16 7 
1 5 2 1 0 12 0 
16 2 0 0 7 0 
17 2 2 1 9 5 
18 2 0 2 6 5 
19 4 0 8 9 0 
20 4 0 0 6 7 
21 4 0 0 12 2 
22 4 3 6 12 0 
23 4 0 2 3 8 
24 4 0 3 2 5 
25 4 0 0 2 12 
26 4 0 0 3 4 





Raw Data f or Boundary of Sham Operated C3H/HeJ Mice 
Sample No. Day PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 8 1 2 3 2 
2 8 0 1 9 4 
3 8 0 2 11 7 
4 8 0 6 1 5 1 
5 8 0 0 12 0 
6 8 0 0 12 4 
7 8 0 3 9 3 
8 8 0 1 10 12 





Raw Data for Boundar y of Liver - Implanted C.3H/HeJ Mice 
-----------------------------------------------------------
Sample No. Days PMNs Lymph Hist Fi b 
-----------------------------------------------------------
1 1 1 5 6 .3 0 
2 1 14 7 10 0 
.3 1 11 9 9 0 
4 1 11 4 17 1 
5 1 18 9 16 0 
6 1 12 8 12 0 
7 1 0 22 7 0 
8 1 .3 12 16 0 
9 1 .3 9 11 0 
10 2 6 6 7 0 
11 2 5 7 16 0 
12 2 9 .3 11 0 
1.3 2 5 8 0 0 
14 2 2 16 19 0 
15 2 8 10 12 2 
16 2 7 12 1 0 
17 2 .3 5 11 0 
18 2 .3 8 1.3 0 
19 4 2 6 1 5 0 
20 4 1 .3 11 2 
21 4 2 14 5 0 
22 4 0 .3 4 0 
2.3 4 1 2 6 1 
24 4 0 11 17 2 
25 4 1 7 16 5 
26 4 2 8 22 .3 





Raw Data for Boundary of Liver-Implanted C.3H/HeJ Mi ce 
Sample No . Days PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 8 0 4 22 0 
2 8 1 1 12 6 
.3 8 1 .3 .30 .3 
4 8 0 .3 10 0 
5 8 0 0 10 0 
6 8 0 .3 7 0 
7 8 0 9 8 7 
8 8 0 8 28 0 





Raw Data for Boundary of Tumor-Impl anted C3H/HeJ ~1ice 
-----------------------------------------------------------
Sampl e No . Days PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 1 5 9 0 0 
2 1 5 6 4 2 
3 1 6 8 8 0 
4 1 6 2 16 0 
5 1 21 10 2 0 
6 1 4 19 9 4 
7 1 67 16 0 0 
8 1 8 12 10 0 
9 1 24 11 11 0 
10 2 15 4 9 0 
11 2 6 1 5 0 
12 2 11 4 12 3 
13 4 1 3 9 2 
14 4 2 5 15 0 
1 5 4 0 2 17 6 
16 4 1 6 17 2 
17 4 0 9 9 1 
18 4 0 4 9 1 
19 4 1 1 21 3 
20 4 1 9 6 0 




Raw Data for Boundary of Tumor-Implanted CJH/HeJ Mice 
Sample No . Days PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 8 1 2 7 4 
2 8 1 4 13 7 
J 8 0 5 14 4 
4 8 2 2 8 1 
5 8 1 J 17 0 
6 8 2 J 15 0 
7 8 1 J 5 3 
8 8 0 2 12 0 




EXPER IMENT II 
Raw Data for Interior of Liver-Implanted C.3H/HeJ Mice 
-----------------------------------------------------------
Sampl e No . Days PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 1 76 16 0 0 
2 1 .3 5 .35 0 
.3 1 16 7 41 0 
4 1 1.3 4 21 0 
5 1 9 2 25 0 
6 1 4 .3 19 0 
7 1 0 .3 7 0 
8 1 .3 .3 21 0 
9 1 5 .3 25 0 
10 2 0 J 0 0 
11 2 0 9 .30 2 
12 2 2 4 1.3 5 
1.3 2 0 .3 0 0 
14 2 .3 8 11 0 
15 2 0 4 11 0 
16 2 2 2 7 0 
17 2 1 1 5 0 
18 2 2 7 8 0 
19 4 .3 8 8 0 
20 4 .3 6 11 1 
21 4 0 6 10 4 
22 4 4 1.3 17 0 
2.3 4 2 9 18 0 
24 4 5 .3 12 0 
25 4 0 4 8 0 
26 4 0 2 15 0 





Raw Data f or Interior of Liver - Impl anted C3H/HeJ Mice 
Sample No. Days PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 8 0 2 1 0 
2 8 0 5 13 4 
3 8 2 2 26 0 
4 8 0 3 11 3 
5 8 0 0 10 2 
6 8 0 1 10 0 
7 8 2 8 29 1 
8 8 1 3 30 0 
9 8 0 0 39 0 
::. 
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Tabl e XIII 
-----------------------------------------------------------
EXPERIMENT II 
RavT Data for Interior of Tumor- Implanted C3H/HeJ Mice 
-----------------------------------------------------------
Sample No . Days PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 1 1 5 3 0 
2 1 3 10 1 5 0 
3 1 5 15 16 0 
4 1 3 7 11 0 
5 1 3 6 0 0 
6 1 2 6 10 0 
7 1 8 15 10 0 
8 1 1 4 6 0 
9 1 2 5 11 1 
10 2 0 5 0 0 
11 2 2 2 0 1 
12 2 2 5 8 0 
13 4 0 3 13 0 
14 4 1 6 20 0 
15 4 0 3 4 0 
16 4 4 12 14 0 
17 4 0 1 20 0 
18 4 0 2 19 1 
19 4 0 3 4 0 
20 4 1 7 5 0 
21 4 0 3 6 2 
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Table XI V 
EXPERIMENT II 
Raw Data for Interior of Tumor-Implanted C3H/HeJ Mice 
Sample No . Days PMNs Lymph Hist Fib 
-----------------------------------------------------------
1 8 4 5 15 1 
2 8 0 3 15 1 
3 8 1 1 14 4 
4 8 4 6 13 2 
5 8 1 20 10 1 
6 8 4 14 10 3 
7 8 0 7 12 0 
8 8 0 7 7 0 
9 8 0 10 10 0 
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Tabl e XV 
EXPERIMENT II 
Mean Values + 1 Standard Error of the Mean 
\vi th Dunnett 1s-t applied for the Boundary of the 
Sham Operated , Liver- and Tumor-Implanted C3H/HeJ Mice 
Cell Days No . of Sham Liver Tumor Results 
Type Obser varions (S) (L) ( T) 
(S) (L) (T ) HEAN MEAN MEAN p- value 






1- 4 27 27 21 
8 9 9 9 
1- 4 27 27 21 
8 9 9 9 








0 . 4 
0 . 24 
- 0 .32 
l~8 . 9 
3 . 25 
H - 2.96 
0 .9 





2 . 35 
1. 7 ***8 .0 ***7 .3 ***p<0 . 01 
0. 46 0. 88 1 . 07 
**- 5. 52 **- 4 .89 **2 .89 
1 • 7 
0. 65 
3. 7 
1 . 0 
- 1.95 
7 .6 *11. 2 
0 . 80 1 . 08 
;~*- 2 . 45 
2 . 8 
0 . 40 
-1 . 08 
p>0 . 05 
2 . 35 
9 .4 l~p<0 . 05 
1. 22 
-1. 24 **2 . 26 







- 0 .60 
p>0 . 05 
1-4 27 27 21 
8 9 9 9 
5. 6 
1 . 00 
3.9 
1 . 22 
0.24 










2 . 35 
lHH~p<O . 01 
**2 .89 
p>0 . 05 
2 . 35 
t = Dunnett 1 s-t value , ct = Critical-t value , (S) = Sham , 
(L) = Liver , (T) = Tumor, SEM = Standard Err or of the Mean . 
* p<0 . 05 and *** p<0 . 01 = significant value . 




Mean Values + 1 Standard Error of the Mean 
with Dunnett 1s-t applied for the Interior of the 
Sham Operated, Liver- and Tumor-Implanted C3H/HeJ Mice 
-----------------------------------------------------------
Cell Days No. of Sham 
Type Observations (S) 
(S) (L) (T) Mean 
+ SEM -
PMNs 1-4 27 21 
8 9 9 
Lymph 1-4 27 21 
8 9 9 
His t 1-4 27 21 
8 9 9 
Fib 1-4 27 21 







0 . 6 






1 • 8 
0 . 45 
1 . 26 
1 .6 
0 . 63 
-1 . 45 
5 . 5 6 . 0 





18 . 8 
4 .18 
0 . 4 
0 . 24 
1 • 1 
0 . 51 
- 0 . 40 
~~8 . 1 
1. 95 
H - 2 . 63 
'~9 . 3 
1.41 




0 . 2 
0 . 12 
0.71 
1 .3 







p>0 . 05 
2 .1 2 
p>0 . 05 
2 . 01 
-~~p<O . 05 
'~* 2 .1 2 
'~p<O .05 
p>0 . 05 
2 .1 2 
p>0 . 05 
2 . 01 
p>0 . 05 
2 .1 2 
t = Dunnett ' s- t value , ct = Critical-t value, (S) =Sham , 
(L) = Liver , (T) = Tumor , SEM = Standard Error of the Mean . 
* p<0 . 05 = Significant Value . 
** t value > ct represents significant results . 
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Tables XVII through XXVIII contain the raw data for 
Experiment III while Tables XXIX and XXX report the mean 
data and corresponding standard error of the mean . 
Experiment III (Table XXIX) shows that the number of 
fibr oblasts seen from day 7 through 14 in the warfarin group 
was significantly (P<0 . 05) l ess than in the control (saline 
injected) group . The number of boundary lymphocytes from 
day 7 through 14 was increased (P<0 . 05) in both the heparin 
and warfarin groups when compared to the saline group. 
Table XXX shows an increased number of tumor cells 
(P<0.01) in the interior of the warfarin group when compared 




Raw Data for Boundary of Tumor-Implanted C3H/HeJ Mice 
with Saline Injection 
Sample No. Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 2 5 5 2 2 10 
2 2 6 6 5 1 9 
3 2 7 10 3 1 4 
4 2 22 4 0 3 0 
5 2 19 4 3 0 0 
6 2 17 4 5 1 0 
7 4 8 4 14 3 0 
8 4 4 3 8 10 0 
9 4 4 4 9 14 0 
10 4 4 4 12 0 3 
11 4 1 0 16 0 0 
12 4 1 9 0 0 
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Tabl e XVIII 
-----------------------------------------------------------
EXPERI MENT III 
Raw Data for Boundary of Tumor-Implanted C3H/HeJ Mice 
with Saline Inj ection 
-----------------------------------------------------------
Sampl e No. Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 7 1 0 2 3 0 
2 7 0 0 5 0 0 
3 7 0 0 6 3 0 
4 7 0 1 10 1 0 
5 7 0 3 4 0 0 
6 7 0 1 6 1 0 
7 9 0 0 5 0 2 
8 9 0 0 4 0 0 
9 9 0 0 4 0 1 
10 9 0 1 3 0 1 
11 9 0 2 1 5 9 3 
12 9 0 1 1 3 1 
13 11 0 0 11 1 0 
14 11 1 0 9 5 0 
15 11 0 2 5 5 1 
16 11 1 0 4 0 0 
17 11 1 0 6 0 0 
18 11 0 0 4 2 0 
19 14 2 0 1 9 0 
20 14 1 0 7 9 0 
21 14 1 0 29 3 1 
22 14 0 0 3 10 0 
23 14 1 0 4 13 0 





Raw Data for Boundary of Tumor- Implanted C3H/ HeJ Mi ce 
with Heparin Injection 
-----------------------------------------------------------
Sampl e No. Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 2 7 12 1 2 0 
2 2 3 2 3 6 1 
3 2 12 3 5 1 0 
4 2 12 5 3 10 0 
5 2 10 8 3 3 0 
6 2 2 3 2 0 0 
7 4 1 2 7 1 0 
8 4 2 1 10 0 0 
9 4 4 3 21 5 0 
10 4 0 2 4 0 0 
11 4 18 1 16 1 0 
12 4 6 10 4 1 
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Tabl e XX 
-----------------------------------------------------------
EXPERIMENT III 
Rar.-r Dat a for Boundar y of Tumor-Impl ant ed CJH/HeJ Mice 
with Hepar in Injection 
-----------------------------------------------------------
Sampl e No . Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 7 2 2 12 6 0 
2 7 4 7 10 J 4 
J 7 0 8 10 J 0 
4 9 2 10 12 3 2 
5 9 1 1 14 0 1 
6 9 4 J 10 9 1 
7 9 0 0 4 0 3 
8 9 0 0 4 0 1 
9 9 0 0 4 0 1 
10 11 1 J 13 1 1 
11 11 0 3 7 1 J 
12 11 0 0 4 0 0 
13 11 0 0 0 0 0 
14 11 2 1 23 0 0 
15 11 1 1 8 4 0 
16 14 1 1 12 0 0 
17 14 0 1 7 4 0 




Raw Data for Boundary of Tumor-Implanted C3H/HeJ Mi ce 
with Warfarin Inj ection 
Sample No. Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 2 20 3 4 4 2 
2 2 14 0 7 5 0 
3 2 1 0 1 0 1 
4 4 5 2 6 2 0 
5 4 10 1 4 0 0 




EXPERI HENT III 
Raw Data for Boundar y of Tumor-Impl anted C3H/HeJ Mice 
wi t h War farin I njecti on 
-----------------------------------------------------------
Sampl e No . Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 7 0 0 18 3 0 
2 7 0 2 8 0 0 
3 7 1 4 17 1 0 
4 7 0 2 7 0 1 
5 7 0 0 13 0 0 
6 7 1 0 7 0 0 
7 9 0 1 5 1 2 
8 9 0 1 5 9 0 
9 9 0 3 5 1 0 
10 9 1 1 6 3 1 
11 9 1 8 13 1 1 
12 9 4 0 8 0 0 
13 11 1 7 9 2 0 
14 11 2 5 16 0 0 
1 5 11 2 11 16 1 0 
16 11 0 0 2 0 0 
17 11 3· 0 1 0 0 
18 11 0 0 2 0 0 
19 14 1 1 5 2 0 
20 14 2 2 16 1 0 




EXPERIMENT II I 
Raw Data for Interior of Tumor- Implanted C3H/HeJ Mice 
with Sali ne Inj ection 
Sample No . Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 2 0 2 2 0 17 
2 2 0 1 2 1 17 
3 2 0 1 0 7 0 
4 2 1 2 1 0 2 
5 2 0 0 0 27 0 
6 2 2 1 3 13 6 
7 4 6 4 10 5 0 
8 4 1 2 11 4 3 
9 4 0 2 3 1 0 
10 4 7 3 9 0 10 
11 4 4 4 10 0 1 
12 4 9 5 9 2 3 
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Tabl e XXIV 
-----------------------------------------------------------
EXPERIMENT III 
Raw Data for I nt erior of Tumor-Implanted C3H/HeJ Mice 
with Saline Injecti on 
-----------------------------------------------------------
Sample No . Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 7 0 0 14 14 5 
2 7 2 0 22 2 4 
3 7 6 0 23 3 3 
4 7 1 4 11 5 1 
5 7 1 3 21 8 2 
6 7 2 6 19 2 0 
7 9 0 4 8 7 8 
8 9 0 1 18 4 5 
9 9 3 1 6 0 10 
10 9 5 2 12 5 1 
11 9 1 4 14 8 14 
12 9 4 3 12 11 6 
13 11 0 2 27 5 3 
14 11 0 3 13 13 1 
15 11 2 3 24 0 6 
16 11 1 4 4 8 1 
17 11 3 4 2 2 0 
18 11 0 3 6 9 0 
19 14 5 1 9 2 1 
20 14 0 1 11 0 4 
21 14 0 3 5 2 3 
22 14 2 1 19 8 2 
23 14 0 0 23 3 1 





Raw Data for Interior of Tumor-Implanted C3H/HeJ Mice 
with Heparin Injection 
-----------------------------------------------------------
Sample No. Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 2 0 3 5 0 16 
2 2 5 2 4 2 12 
3 2 5 2 3 5 8 
4 2 4 1 7 5 4 
5 2 0 1 7 8 3 
6 2 1 0 7 4 7 
7 4 4 2 19 2 6 
8 4 10 5 13 0 7 
9 4 2 1 3 1 1 
10 4 0 1 13 0 7 
11 4 5 1 7 3 1 






Raw Data for Interior of Tumor-Implanted C3H/HeJ Mice 
wi t h Heparin Inj ection 
-----------------------------------------------------------
Sample No. Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 7 0 0 7 17 0 
2 7 2 1 5 21 2 
3 7 2 1 1 5 5 3 
4 9 2 5 22 0 2 
5 9 10 1 10 1 6 
6 9 0 4 7 1 16 
7 9 4 1 26 0 13 
8 9 0 1 23 0 7 
9 9 0 3 26 1 4 
10 11 1 1 40 3 5 
11 11 1 4 12 2 3 
12 11 1 0 11 9 0 
13 11 2 7 10 1 3 
14 11 1 0 20 4 4 
1 5 11 5 0 20 5 3 
16 14 2 1 12 0 18 
17 14 0 1 24 1 0 




Raw Data for Interior Tumor-Implanted C3H/HeJ Mice 
with Warfarin Injection 
Sample No . Days PMNs Lymph Hist Fib Tumor 
-----------------------------------------------------------
1 2 7 4 2 0 50 
2 2 13 4 1 0 37 
3 2 0 0 0 0 73 
4 4 1 2 1 0 0 
5 4 11 2 11 2 1 





Raw Data for Interior of Tumor-Implanted C3H/HeJ Mice 
with Warfarin Injection 
-----------------------------------------------------------
Sample No . Days PMNs Lymph Hist Fib Tumor 
------------------------------------------,----------------
1 7 9 2 20 5 4 
.2 7 3 7 .2.2 J 2 
3 7 7 4 13 1 1 
4 7 0 .2 15 2 5 
5 7 5 4 14 .2 1 
6 7 2 2 13 0 0 
7 9 1 J 15 10 3 
8 9 0 7 7 6 1 
9 9 0 5 10 0 0 
10 9 0 .27 15 7 0 
11 9 0 78 2.2 0 0 
12 9 4 34 .24 7 1 
13 11 1 1 5 2 0 
14 11 1 0 14 2 1 
15 11 1 0 15 1 3 
16 11 0 0 14 6 0 
17 11 0 0 20 9 0 
18 11 1 0 .20 1 0 
19 11 1 1 31 5 6 
.20 11 2 1 40 .2 4 





Mean Values + 1 Standar d Error of the Mean 
with Dunnett ' s-t applied for the Boundar y of the 






Days No . of 
Observations 
(S) (H) (l,V) 
1-4 12 12 6 
--------------
7-14 24 18 21 
1-4 12 12 6 
--------------
7- 14 24 18 21 
1-4 12 12 6 
--------------




8 . 2 
2 . 06 
0.4 
0 . 12 
4. 1 





6 . 5 
1 • 18 
Heparin Warfarin 
Mean Mean -- --+ SEH + SEM - -t= t= 
6 . 4 10 . 2 
1.60 2 . 73 
0 .61 - 0 . 70 
1.0 1 . 0 
0 . 31 0.24 
-1 . 98 -1 . 83 
3 . 6 2. 0 
0 . 96 0. 93 
0 . 41 1. 66 
'~2 · 4 '~2 . 4 
0 . 70 0. 66 
*- 2 . 66 '~-2 . 57 
7 . 1 5. 7 
1 . 78 1. 52 
0 . 04 0 . 63 
9 . 3 9 . 1 
1 . 24 1 . 18 




p>0 . 05 
2. 34 
p>0 . 05 
2 . 27 
p>0 . 05 
2 .34 
·:<p<O . 05 
*2 . 27 
p>0 . 05 
2.34 
p>0 . 05 
2. 27 
------------------------------------------------------------
Fib 1- 4 12 12 6 2.9 2 .8 1 . 8 p>0 . 05 
1. 29 0 .88 0 . 91 
-------------- 0 . 10 0 . 68 2 . 34 
7- 14 24 18 21 4. 0 2 . 3 '<1 .2 '<p<O . 05 
1 . 05 0. 66 0 . 45 
1 . 87 *2 . 48 '~2 . 27 
Tumor 1- 4 12 12 6 2. 2 0 . 2 0 . 5 p>0 . 05 
1. 06 0 . 11 0 . 34 
-------------- 1 . 87 1. 56 2 . 34 
7-14 24 18 21 0 . 4 1 • 0 0 . 2 p>0.05 
0 .16 0. 29 0. 12 
-2.17 0 .66 2 . 27 
t = Dunnett ' s- t , ct= Critical- t , (S)= Saline , (H)= Heparin, 
(W)= Warfarin , '~p<0 . 05= Significant Value with t value > ct . 
SEM= Standard Error of the Mean . 
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Tabl e XXX 
EXPERIMENT III 
tv!ean Values + 1 Standard Error of t he tv!ean 
with Dunne t t ' s - t appli ed for the Inter ior of the 




Days No . of 
Obser vations 
(S) (H) (W) 
1-4 12 12 6 
--------------
7-1 4 24 18 21 
Sali ne Heparin Warf ari n Results 
tv!ean Mean 
+ SEM + SEM - -t = 
2 . 5 3 . 8 
0 .92 0 . 97 
- 0 . 74 
1 . 7 1. 9 
0 .38 0 . 58 




5 . 7 
2. 25 
- 1 . 87 
1. 9 
0. 54 






2 . 27 
------------------------------------------------------------
Lymph 1-4 12 12 6 2.3 1. 7 2. 0 p>0 . 05 
0 . 43 0 . 38 0 . 73 
-------------- 0 . 88 0 .38 2 .34 
7- 14 24 18 21 2 . 4 1. 9 8 . 8 p>0 . 05 
0 . 35 0 . 47 3.96 
0 . 16 -1 .95 2. 27 
Hist 1-4 12 12 6 5 . 0 8 . 2 3 . 2 p>0 . 05 
1. 26 1 . 39 1 . 66 
-------------- -1 . 57 0 .91 2 . 34 
7- 14 24 18 21 14 . 6 17 . 4 18 . 3 p>0 . 05 
1. 57 2. 14 1. 90 
- 1 . 07 -1 . 39 2. 27 
Fib 1-4 12 12 6 5 . 0 2. 5 0 . 5 p>0 .05 
2 . 29 0 . 74 0 . 34 
-------------- 1. 05 1 .88 2 . 34 
7-1 4 24 18 21 5 . 2 4. 1 3 . 6 p>0 . 05 
0. 82 1. 40 0 . 66 
0 . 82 1 . 18 2 . 27 
------------------------------------------------------------
Tumor 1- 4 12 12 6 4 .9 6 . 2 '~26 . 8 ><p<O. 01 
1 . 84 1. 30 12. 75 
-------------- - 0. 20 '~- 3 . 42 *3 . 04 
7- 14 24 18 21 3 .4 5 . 1 1. 5 p>0 . 05 
0 . 71 1. 25 0 .41 
- 1 . 43 1 • 65 2 . 27 
t = Dunnett ' s - t , ct= Critical-t , (S)= Sali ne , (H)= Hepari n , 
(W) = Warfarin , '~p<O . 01 = Signi ficant Value with t val ue > ct . 
SEH= St andard Er ror of the tv!ean . 
DISCUSSION AND ANALYSIS 
In normal transplant rejection, histoincompatible 
cells from the donor would activate the immune response in 
the recipient . This would activate all aspects of the 
defense system (macrophages, B lymphocytes, T lymphocytes , 
and complement) of which the macrophage and the T lymphocyte 
would be the most effective . Therefore , in human organ 
transplant recipients every effort would be used to suppress 
the immune response so that the transplant graft tissue 
could survive . Studies of privileged tissues, graft sites, 
and antigeni c tol erance have been important i n 
developing methods to escape t he graft rejection 
phenomenon(20). 
The tumor cells used in each of the three experiments 
have some antigenic similarity to host cells but are not 
antigenically identical to t hem . For this 
clear if the host ' s immune response 
activated and fails to reject the tumor 
reason it is not 
is incompletely 
or if fac tors 
released by the tumor (angiogenesis factors, vascular 
permeability factors, enhancing factors , or blocking 
factors) enhance rather than inhibit tumor growth(20) . 
Many but not all animal tumor cells have tumor specific 
antigen on their surfaces . Most of these antigens are 
immunogeni c and produce either a humoral or cell-mediated 
immune response . The cell-mediated (T lymphocyte) response 
47 
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may be neutralized by serum-blocking factors . It is 
possible that tumors fail to be recognized by the immune 





The goal of Experiment I was to become familiar 
parenchyma and stroma of CJH/HeJ mouse mammary 
spontaneous and passaged in order to evaluate 
morphologic responses to experimental procedures . 
Familiarity with the parenchyma and stroma was achieved by 
reviewing slides of tumor samples from each spontaneous 
tumor mouse under light microscopy at 400 power . These 
slides were then compared to slides of tumor samples 
from corresponding first and second transplant t umor mi ce , 
respectively. Slides were reviewed first for acinar or 
glandular arrangement of the mouse mammary tumor as compared 
to the normal mouse mammary glands ; second for the presence 
or absence of intraluminal secretions (the presence of 
secretions indicating a more normal functional mammary 
tissue and the absence of secretion indicating a mor e 
diffuse, less differentiated , and more neoplastic 
development) . Third, the tumor cells were observed for 
presence or absence of cytoplasm around their nuclei . 
The presence of cytoplasm was associated with acinar or 
glandular arrangement . The absence of cytoplasm was noted 
in the presence of increased cellularity . 
As observed in Table IV, some spontaneous mouse 
mammary tumors were more anaplastic than others . ST4 was 
the most anaplastic with a cellular density comparable to 
49 
that seen after the second passage in the other three 
groups . 
Since tumors become more anaplastic with each 
transplantati on(1 1) i t would appear that ST4 had become very 
anaplasti c spontaneously , resulting possibly in a greater 
concentration of cells prior to implant . This phenomenon 
cannot be explained by rapid tumor growth alone , but is 
related to increased malignancy referred to as tumor 
progression . The phenomenon is also observed in an 
advanced tumor in a host over time . In tumor progression the 
progeny of cancer cells exhibit i ncreas i ngly malignant 
characteristics , whereas , the progeny of healthy cells are 
usually faithful copies of their parent(1 1 ) . As might be 
expected with an increased tumor concentration , necrosis was 
observed in TP4- 1 and TP4- 2 (sequential transplants 1 and 2 
of spontaneous tumor number 4) indicating inadequate blood 
supply and cell death . 
In contrast , ST1 (Table IV) had a very low cell 
density with no tumor cells noted until after two 
transplants (TP1-1 and TP1 - 2) , and with tumor cells noted 
only in TP1 - 2. Since approximatel y 10 mg of tumor was 
implanted into each mouse , it would seem clear that part of 
the 10 mg implanted from ST1 was fat or muscle with a very 
small number of tumor cells present . The general absence of 
tumor also explains the absence of glandular arrangement , 
secretions and cytoplasm , since there would be a decreased 
amount of mammary tissue transplanted as well. 
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Spontaneous tumor number two (ST2) had a glandular 
arrangement present with secretions and cytoplasm . The 
morphology was very similar t o normal mammary tissue and 
suggests a less malignant tumor. The transplants (TP2- 1 and 
TP2-2) seem to conf irm the initial observation since the 
glandular arrangement decreased but was still present after 
the second transplant (TP2- 2) and the cytoplasm r emained 
present , but associated only with acinar arrangement . One 
indication of increased malignancy or tumor progression was 
the absence of secretions in TP2-1 and TP2-2 where it was 
present in ST2 . 
STJ appear ed t o be mor e anaplas t ic than ST2 but l ess 
than ST4 . In the original sampl e , there was some glandular 
arrangement noted , with secretions and cytoplasm present , 
but with one transplant (TPJ-1) all glandular arrangement , 
secretions and cytoplasm disappeared indicating a relatively 
more malignant tumor . TPJ- 2 confirmed the pattern of 
change with a densely increased cellularity . 
In summary the order of malignancy proceedes from 
ST4 > STJ > ST2 > ST1 . Progressive tumor developement is 
indicated by a decrease or absence of glandular arrangement , 
secretions and cytoplasm , with an increase in cellularity . 
It should be noted that not all tumors are equally malignant 
but all progress toward anaplasticity . 
Experiment II was expected to demonstrate a wide range 
of leukocytic activity with early inflammatory response to 
the sham operation and liver implantation . An increase in 
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neutrophil (PMN) and macrophage activity 1vas expected 
due to possible inflammation caused by dead liver cells . 
As seen in (Tabl e TV) there Has a stastically significant 
(P<0 . 05) increase in boundary PMNs between days 1 and 4 
for the tumor-implanted mice , when compared to the sham 
operated mice . There Has also an increase in the boundary 
PMNs between days 1 and 4 for the liver-implanted mice, Hhen 
compared to the sham operated mice. However, the change 
was not statistically significant by day 4 with a resolution 
of the inflammation and a reduction of P~~s in all three 
groups by day 8 . These results seem to indicate a nor mal 
immune response by PMNs to both liver and tumor impl ants . 
These data also indicate that the tumor was at least as 
exposed to PMN attack as the liver, since a significantly 
larger mean value of PMNs was observed for the tumor-
implanted group than for the liver- implanted group . This 
increase in PMNs is probably related to the phagocytic 
activi ty of the PMNs(20) and the antigenic exposure on the 
tumor cells . It should also be noted from Table XVI that 
early , day 1 through day 4, there was less PMN penetration 
into the tumor when compared to liver. This difference can 
be explai ned in terms of phagocytosis of dead liver cells 
compared to viable tumor cells or in terms of the tumor 
preventing penetration by a protective mechanism(12) . 
An increased day through 4 boundary lymphocytic 
response was observed in both liver- and tumor-implanted 
groups when compared to the sham operated group . Values for 
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both liver- and tumor-implanted boundary lymphocytes were 
statistically increased (P<0.01). These increases may 
reflect the presence of surface antigens on the tumor or a 
lack of blocking ability by the tumor , and a response to 
decaying necrotic tissue from the liver implant . Table XVI 
demonstrates a late day 8 increase (P<0 . 05) in the number of 
lymphocytes penetrating the tumor implant when compared to 
the number of lymphocytes penetrating the liver implant . 
This increase may be related to the death of the liver 
implant and the continued viability of the tumor implant . 
The increased (P<0.05) number of day through 4 
boundary histiocytes observed in the liver-impl anted group 
when compared to the sham operated group further supports 
the possibility of immune response to decaying necrotic 
liver cells . Table XVI further supports this observation 
with a decrease (P<0.05) in the day 1 through 4 number of 
histiocytes penetrating the tumor implant when compared to 
the liver implant . This could indicate histiocytic response 
to necrotic t i ssue in the liver or a decreased response to 
the tumor implant due to its protective mechanism , or a 
combination of the two . Since histiocytes are nonspecific 
in inflammatory response, an increase was expected in all 
three groups due to the implantation procedure alone . The 
late decrease in histocytic response to the tumor implant 
when compared to the liver implant in Table XVI and in Table 
XV, although not statistically significant , approaches the 
inflammatory r esponse observed in the sham operated group i n 
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Table XV . This would seem to indicate that the tumor 
is protected and that the necrotic liver implant is being 
exposed to phagocytosis . 
The increased lymphocytic infiltrate coupled with the 
decreased hi stocyti c influx into the tumor 's interior 
suggest that despite an immune presence, amplification of 
responses (i . e ., increased histiocytes) are quelled . This 
follows Dvorak's finding of MIF releas e by tumor cells(12). 
The reason for a significant decrease (P<0 . 01) in the 
number of fibrobl asts observed from day 1 through 4 in both 
the liver- and tumor- implanted groups when compared to the 
sham operated group is unclear , but may be related to 
stretching of the tissue caused by the implants and by 
edema . Later , with decreased edema , as the inflammation 
resolves and repair gets underway a relative incr ease i n the 
number of fibroblasts would be expected in the liver- and 
tumor-implanted groups . This increase was observed (Table 
XV) in both the liver- and tumor- implanted groups , although 
not statistical ly significant . 
One theory of tumor adaptability is that tumors rel ease 
factors such as : 1) vascular permeability factor which 
causes the blood vessels to become leaky; 2) procoagulation 
factor which can cause a clot to form around the tumor (a 
fibrin cocoon) ; and 3) pl asmin (proteol ytic enzyme) 
activator factor which breaks down the fibrin cocoon . The 
fibrin cocoon could cause a decrease in visibility of 
the tumor to the immune system by covering up the surface 
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antigen . There is also some evidence that the fibrin 
cocoon is related to angiogenesis possibly stimulating 
the development of new blood vessel formation(21) . 
Tumor angiogenesis factor is a diffusable chemical 
substance which is released from tumor cells. It has the 
capacity to stimulate nearby blood vessels to send out ne\-T 
capillaries that grow toward the colony of tumor cells and 
finally penetrate it . Rapid tumor growth then folloHs \·li th 
fresh nutrients poured in and wastes speedily removed(11) . 
Given these findings and others from Santer(17) the 
tumor implants of Experiments I and II were expected to 
cause angiogenesis with rapid growth , with an increased 
null cell population , a decreased number of T l ymphocytes 
and an unchanged number of B lymphocytes . The results of 
Experiment I (Table IV) did indicate a more anaplastic 
growth pattern with first and second passage of the tumor 
which Has also demonstrated by Folkman( 11 ) . However , 
there was no decrease , but an increase in total overall 
lymphocyte response to both liver- implanted and tumor -
implanted CJH/HeJ mice in Experiment II (Table XV and Table 
XVI) , when compared to the sham operated group . Again , 
these increases may reflect the exposure of surface antigens 
on the tumor i mpl ant or a lack of blocking abili ty by the 
tumor, and a response to decaying necrotic tissue from the 
liver implant . 
Experiment III was designed to study the effects of the 
fibrin cocoon and to analyze changes which might occur if 
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the fibrin protection was removed by the use of heparin or 
warfarin . Both heparin and warfarin act by different 
mechanisms to inhibit or prevent fibrin cocoon formation. 
If the fibrin pr otecti on was necessary for angiogenesis(21) 
a reduced growth of tumor in the mice on heparin or warfarin 
versus the control mice on saline could be anticipated, with 
an increased immune activity if the fibrin had blocked 
recognition in those mice on anticoagulants . 
Based on the studies by Folkman(11) and Santer(17) 
early increased PMN and macrophage activity should be 
seen in the saline control group , with inflammation from the 
implantation procedure. Later there should have been 
an i ncrease in angi ogenesis , a rapid growth of the tumor , 
and an increase in null cell s , with a decrease in T 
lymphocytes and no change in B lymphocytes. 
In the heparin and warfarin treated tumor mice early 
increases in PMN and macrophages would be expected if 
an inflammator y response was caused by 
procedure . However, a decrease in 
the implantation 
angiogenesis with 
decreased growth of the tumor would occur if the fibrin 
cocoon was important in tumor protection and development . 
An increase in null cell activity associated with 
transpl ant tumors and an increase in T lymphocytes 
and B lymphocytes has been observed(17) . With decreased 
tumor protection , normal immune surveillance should produce 
these increases. Antigens should be exposed on the surface 
of the tumor cells and B lymphocytes should have been 
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stimulated to produce antibodies as a late development . 
As seen in Table XXIX there was a general increase i n 
the number of PMNs from day 1 through 4 , probably related to 
the inflammation caused by the implantation procedure used 
to implant the tumors . By day 7 through 14 there was a 
decreased number of PMNs at the boundary of the saline 
injected group when compared to the heparin and warfarin 
injected groups . The results are not statistically 
significant but a trend toward decreased protection of the 
tumor in the heparin and warfarin groups seems possible with 
a resolution of the inflammation resulting in an overal l 
decrease in boundary PMNs . Table XXX further supports this 
assumption in that days 1 through 4 show a greater number of 
PMNs penetrating to the interior of the tumor in the heparin 
and warfarin groups when compar ed to the saline group , but 
again , the numbers are not statistically significant. These 
trends seem to indicate an increased immune response in the 
heparin and warfarin groups when compared to the sali ne 
group . This could be explained by a decrease in the 
protective fibrin-gel hypothesized by Dvorak(12) . 
As indicated in the studies by Folkman(11) and 
Santer(17) there was a late increase (Table XXIX) in the 
number of lymphocytes in the heparin (P<0 . 05) and warfarin 
(P<0 . 05) groups when compared to the saline group . This late 
increase in lymphocytes in both the heparin and warfarin 
groups indicates less surface protection of the tumor from 
immune surveillance. Tabl e XXX projects a similar trend 
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when comparing the late warfarin group to the saline group 
but the increase is not statistically significant . There is 
an early (day 1 through 4) and late (day 7 through 14) 
increase in the number of lymphocytes in the interior of the 
saline group when compared to the heparin group , but the 
. 
increase is not significant and the reason is unclear. 
Activation of macrophages probably occurs when an 
antigen activator stimulates thymus- derived lymphocytes that 
may produce histologically active molecules responsible for 
modification of macrophage function. Activated macrophages 
spare contact-inhibited cells regardless of the antigen 
composition ~t 
regardless of the 









expression of the neoplastic phenotype. This is considered 
a nonimmunologic response. Immune macrophages response is 
different and is specific for target cells(1J). 
There seems to be a trend toward late (day 7 through 
14) histiocyte or macrophage activity in both the heparin 
and warfarin groups when compared to the saline group in 
Table XXIX. This same trend is observed in Table XXX with 
increased penetration into the tumor by histiocytes in the 
heparin and warfarin groups . Although, the numbers are not 
significantly increased , there seems to be a trend toward 
increased macrophage activity in the ant icoagulated groups 
at the boundary and in the interior ,indicating less 
protection, when compared to the sal ine group. 
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There is a decreased (P<0 . 05) number of fibroblasts in 
the day 7 through 14 warfarin group (Table XXIX) when 
compared to the saline group . This could be the result of 
decreased clot formation , due to the warfarin , leading to a 
decrease in the number of fibroblasts and decreased wound 
healing or repair. It should also be observed fr om day 
through 4 that there is a larger number (P<0 . 01) of tumor 
cells (Table XXX) i n the warfarin group than in the sal ine 
group . It is interesting to 'note that with early day 
through 4 decrease in fibroblasts that there is an incresae 
(P<0 . 01) in the number of tumor cells. This may be due to 
the decreased contai nment of the tumor with decreased 
fibroblasts . However, the reason for an increased (P<0 . 01) 
number of tumor cells in the warfarin group when compared to 
the saline group is unclear. 
SUMMARY 
Three separate experiments were conducted to determine 
the nature of leukocytic response to mouse mammary tumor 
implants in CJH/HeJ mice with and without anticoagulants . 
In Experiment I the investigator became familiar with 
the parenchyma and stroma of spontaneous and passaged 
CJH/HeJ mouse mammary tumors in order to evaluate 
morphologic responses to experimental procedures . A light 
microscope was used to look at the morphology of spontaneous 
and passaged CJH/HeJ mouse mammary tumors. Four CJH/HeJ 
spontaneous tumor mice were used in the experiment . A 
single segment of approximately 10 mg of t umor from each 
mouse was implanted into two virgin female C3H/HeJ mice . 
Three weeks after the implantation the two mice (first 
passage) were sacrificed . A segment of tumor from one mouse 
was implanted into a normal mouse and a segment of the 
second tumor was implanted into a second normal mouse . 
Three weeks later the two mice (second passage) were 
sacrificed . 
The following conclusions a ppear justified from 
Experiment I : 
(i) Acinar or glandular arrangement of the mouse 
mammary tumor decreases as the tumor becomes 
more metastatic . 
( ii) Secretions as so cia ted i-Ti th a normal function-
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al mammary tissue decreases and becomes 
absent in advanced spontaneous mouse mammary 
tumors and with first and second passage as 
the tumor becomes more anaplastic . 
(iii) Cytoplasm around the nuclei of the tumor 
cells decreases with increasing numbers of 
cells . The cytoplasm becomes absent in t he 
presence of dense cellularity seen with 
advanced spontaneous tumors and when the 
tumor becomes more anaplastic. 
Experiment II characterized the leukocytic response to 
implanted CJH/HeJ spontaneous tumor segments by contrasting 
that response with those of syngeneic mice with implants of 
normal (liver) tissue and mice that were sham operated upon . 
Three groups of 12 mice (Tabl e II) were used t o conduct the 
experiment . A f emale donor CJ H/HeJ mouse with a 
spontaneous mammary tumor and a normal mouse were sacri ficed 
to obtain tumor and liver for implant ing the two groups of 
twel ve mice . Each of the three groups were observed for 
changes in pol ymorphonuclear 
(Lymphs), histiocyt es (Hist) , 
cells (PMNs) , lymphocytes 
and fi broblas t s (Fi b) around 
the boundary of the implant site and, where applicable, in 
the interior of the liver or tumor . 
The following concl usions appear justi f i ed i n 
Experiment II : 
(i) There was a greater (P<0 . 05) immune response 
(Table XV) by boundary PMNs between days 1 
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and 4 in the tumor-implanted mice when 
compared to the sham operated mice . This 
indicates that the tumor implant was at least 
as exposed to attack by PMNs as the liver 
i mplant , since a significantly larger mean 
value of PMNs was observed for the tumor-
implanted group than for the liver-implanted 
group . 
(ii) There were approximately 66% fewer PMNs 
penetrating to the interior of the tumor 
implant than was observed penetrating the 
interior of the liver implant . Thi s may 
indicate interior protection by the tumor by 
some mechanism different from the liver , 
however the results were not statistically 
significant . 
(iii) The lymphocyte response (Table XV ) was 
(iv) 
significantly (P<0 . 01) increased in both the 
liver- and tumor- implanted groups 
compared to the sham operated group . 
when 
These 
increases may reflect t he presence of surface 
antigens on the tumor or a lack of blocking 
ability by the tumor, and a response to 
decaying necrotic tissue from the liver 
implant. 
Table XVI demonstrates a late day 8 increase 
(P<0 . 05) in the number of lymphocytes 
62 
penetrating the tumor implant when compared 
to the number of lymphocytes penetrating the 
liver implant. This increase may be related 
to the death of the liver implant and the 
continued viability of the tumor implant . 
(v) The boundary histiocyte response between days 
and 4 was greater (P<0.05) in the liver 
implant group when compared to the sham 
operated group. This probably indicates an 
immune response to decaying necrotic liver 
cells. 
(vi) The interior histiocyte r esponse between days 
1 and 4 was significantly less (P<0 . 05) in 
the tumor-implanted group when compared to 
the liver- implanted group probably related to 
protective mechanisms and to the viability 
of the tumor compared to the decaying liver 
tissue. 
(vii) The fibroblasts were significantly ( P<O . 01 ) 
less around the tumor and liver implants. 
This reduction in number was probably related 
to edema and stretching produced by the 
implants with insufficient time by day 4 for 
repair . 
Experiment III described changes in leukocytic response 
to tumor implants in control (saline injected) tumor- bearing 
mice versus heparin or warfarin injected tumor-bearing mice. 
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Three groups of 12 mice were implanted with tumors . 
One group was injected over 14 days with saline , a second 
group with heparin and the third group with warfarin. 
The following conclusions appear justified f rom 
Experiment III : 
(i) There was a general incr ease in the number of 
PMNs f rom day 1 through 4, probably related 
to the inflammation caused by the 
implantation procedure used t o implant the 
tumors . 
(ii) There was a late i ncrease (P<0 . 05) in t he 
number of lymphocytes in both the heparin and 
warfarin groups when compared to t he saline 
group (Table XXIX) . This late i ncrease in 
lymphocytes in both the heparin and warfarin 
groups indicates l ess surface protection of 
t he t umor from immune surveillance . 
(iii ) The number of fibroblasts was significant ly 
(P<0 . 05) reduced at the boundary of the 
warfarin group between days 7 and 14 
(Table XXIX). This could be the result of 
decr eased clot formation due to the warfarin 
l eading to a decrease in the number of 
f ibroblasts and decr eased wound healing and 
repair . 
( iv) There was a s i gnificant increase (P<0 .01) in 
the number of tumor cells (Table XXX) in the 
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warfarin group when compared to the saline 
group . The reason for this increase in 
unclear . The increase may have been 
related to the number of viable tumor cells 
implanted, or to the blood supply to the 
tumor from the host , but furthe r research 
seems indicated . 
The nature of leukocytic response to mouse mammary 
tumor implants in CJH/HeJ mice with and without 
anticoagulation seems to be varied . 
The author found significant increases in the number of 
neutrophils (PMNs) (P<0.05) , lymphocytes (P<0.01 ), and 
fibrocytes (P<0 . 01) in the tumor-implanted group when 
compared to the sham operated group of CJ~/HeJ mice i n 
Experiment II (Table XV). There was also an incr ease 
(P<0.05) in the number of lymphocytes on day 8 (Tabl e XV I ) 
in the tumor- implanted group when compared to the liver-
implanted group of CJH/HeJ mice . All of t hese responses 
may be indicat ive of a normal host immune r esponse to an 
inflammatory procedure (i . e ., the impl ant ation procedure 
used to implant the liver and tumor ) in non- coagulated 
CJH/HeJ mi ce . 
Experiment III (Table XXIX) , which has tumor implants 
i n all three groups , shows a s i gnificantly i ncreased number 
of lymphocytes (P<0 . 05) from day 7 through 14 in the heparin 
and warfarin inj ect ed groups when compared to the saline 
injected group of CJH/HeJ mice . There was also a decreased 
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(P<0 . 05) number of fibroblasts in the day 7 through 14 
warfarin injected group when compared to the saline in j ected 
group . Table XXX shows a day 1 through 4 increase (P<0 . 01 ) 
in the number of tumor cells in the warfarin injected 
when compared to the saline injected group . All of 
group 
this 
information seems to indicate that the tumor is protected in 
the saline injected group and that the tumor is exposed in 
t he anticoagula t ed (heparin and warfarin) groups , with the 
warfarin group being more exposed than the heparin group . 
The decr eased numb er of fibrocytes in the warfarin group 
could represent less confinement of the tumor or greater 
exposure of the tumor. 
The l evels of significance found throughout Experi ments 
II a nd III indicate that this new area of s tudy deserves 
furt her research with the hope of improved response , in a 
clinical sense , in the patient with metastatic cancer . 
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